Chair Bridget Coates framed the year as balance-sheet first.
Restoring profitability and completing the recapitalisation were the Board's most critical focus areas in FY26. Together, these actions significantly strengthened Comvita's financial position and created a more stable platform for the future.
She said the gains “reflect genuine financial discipline across the business and deliberate actions taken under Comvita's reset programme,” in the same 28 August NZX release.
CEO Karl Gradon, permanent from late July 2025 after roles at Miraka, NZ Mānuka Group and Fonterra, pointed forward.
Our focus now is on continuing to improve operational performance and returns, while pursuing targeted growth opportunities and maintaining financial discipline.
Company-owned apiaries delivered strong yields. Comvita shipped about 765 tonnes of incremental Mānuka volume year on year, the company said.
H1 FY26 had already previewed the path. Revenue was $118.0 million, up 18.3 percent. NPAT was $4.6 million. Normalised EBIT was $10.0 million. Net debt had fallen to $48.7 million and inventory to $68.3 million by 31 December 2025, per the 23 February 2026 half-year release. A March 2026 trading update lifted normalised EBIT guidance to about $15.5 million from roughly $14.3 million. Full-year GAAP operating profit of $14.0 million landed close to that band after residual items.
How the operating machine turned
Six linked mechanisms drove the swing.
First, US club-retail volume cleared aged high-cost stock and lifted plant overhead recovery in New Zealand. North America sales rose 104.3 percent and became Comvita’s largest market, the company said in its FY26 release.
Second, operating expenses fell 10.7 percent, or about $12.2 million, to $100.8 million. Cost of sales dropped 12.6 percent. ERP and transformation spend tapered after earlier years of heavy investment.
Third, geographic mix improved realised margin. Greater China sales fell 4.7 percent and profit 12.1 percent amid value-conscious spending. Rest of Asia sales grew 6.2 percent with profit up about $3.3 million. EMEA rose 15.8 percent. ANZ fell 5.8 percent.
Fourth, working-capital discipline converted inventory into cash and debt paydown. The H1 trough of $68.3 million partially rebuilt to $79.9 million by year-end as harvest needs normalised, still far below the prior peak.
Fifth, the equity injection and refinance cut interest burden and removed the covenant cliff. Facilities had been due in early 2026. Banks extended conditional on at least $25 million of new equity. The raise delivered more.
Sixth, leadership refreshed execution. Mandy Tomkins-Dancey became permanent CFO. Michael Chye joined as F&N’s board nominee on 22 June 2026. Julia Xu and Peter Nathan joined on 20 July. Emma Blott became chief commercial officer.
Underlying operating improvement was not merely the absence of write-downs. Combined FY24–FY25 impairments and provisions exceeded $130 million. FY24 impairments were $64.2 million before tax. FY25 carried $53.9 million of impairments plus $15.1 million inventory provisions and a $3.5 million biological-asset fair-value write-down, according to the FY25 annual report and results presentation. Underlying NPBT losses before impairments sat near $22 million in both years. FY26’s $14.0 million operating profit therefore marks a roughly $36 million operating swing plus balance-sheet repair.
Capital markets: the scheme that failed and the raise that stuck
On 14 November 2025, shareholders failed to approve Florenz’s scheme at $0.80 cash. Interest Class 2 delivered only 54.29 percent For, short of the 75 percent cast-vote threshold. Only 44.25 percent of total voting rights favoured the deal, short of a bare majority of all shares, the Takeovers Panel register and Comvita’s 17 November NZX notice record. The Scheme Implementation Agreement terminated the same day.
Florenz, associated with Mark Stewart and Masthead and holding Wedderspoon Organic among other brands, had implied equity value of about $56 million and enterprise value of about $119 million—a 67 percent premium to the 15 August 2025 close. Grant Samuel’s independent adviser range was $0.70–$0.92 per share (equity $49.6–$64.6 million). Li Wang and China Resources had committed via voting agreements. The NZ Shareholders’ Association leaned in favour on execution-risk grounds for a low-liquidity stock. A blocking minority of retail and other holders killed the transaction.
Share price briefly traded in the low-40s to low-50s. Banks extended facilities first to 30 April 2026, then to 31 May, conditional on recapitalisation of at least $25 million. Drawn debt had been about $71.6 million of $94 million facilities at end-FY25.
On 15 April 2026 Comvita launched a 1-for-1.53 renounceable rights offer at $0.65, maximum about $30 million off 70,561,746 existing shares, partially underwritten by F&N Ventures, plus a strategic placement at $0.80 to take F&N to 19.99 percent. The rights price was a 4.4 percent discount to the last trade of $0.68 on 14 April and sat below Grant Samuel’s $0.70 floor on a spot basis.
Close on 12 May secured $40.5 million: $30 million rights plus $10.5 million placement. Eligible take-up was about 69 percent, rising to roughly 72 percent effective with oversubscription—31.8 million new shares for $20.7 million plus 1.5 million additional for about $0.99 million. Shortfall of 12.8 million shares ($8.3 million) went to F&N at $0.65. Placement of 13.2 million shares at $0.80 delivered the balance. Post-raise ordinary shares on issue approximated 130 million. PHC Investments emerged around 13 percent pre-dilution and about 11.7 percent after, holding 15.24 million shares. F&N’s 19.99 percent implied roughly 26 million shares.
Refinancing delivered a $43.9 million revolving credit facility maturing September 2028, with $25.5 million undrawn at balance date. Net cash removed the going-concern overhang that had hung over the NZX Main Board small-cap name.
Yahoo Finance data show CVT.NZ around $0.79 in late August 2026, with a 52-week high of $0.835 and low of $0.43. Year-to-date recovery ran about 59 percent into the results window. Market capitalisation sat near $103–107 million on the enlarged base.
Sector setting: premium honey, correcting supply, US demand
New Zealand remains the world’s highest-value natural honey exporter. World’s Top Exports data place NZ first by value in 2025 at US$280.9 million, or 11.3 percent of a US$2.48 billion global market, ahead of mainland China, India, Argentina and Ukraine. WITS/Comtrade corroborates about US$280.6 million. Tiny volume share still commands premium price because of Mānuka.
MPI’s December 2025 Situation and Outlook for Primary Industries forecasts honey export revenue of $430 million for the year to June 2026, from $426 million, and $440 million in 2027. Average monofloral mānuka prices had dropped about 8 percent to $41.81/kg by September 2025. Total food-and-fibre exports hit $60.4 billion in YE June 2025 and are forecast $62.0 billion in 2026. Honey sits inside a processed-food band near $3.4 billion—small but high-margin.
The industry has been correcting multi-year oversupply. Registered beekeepers fell to 7,874 at 1 June 2025 from 8,592 a year earlier, NZ Bee Health & Biosecurity reported. AFB cases dropped 15.4 percent with the first annual incidence decline in four years. IBISWorld estimates beekeeping industry revenue near $448 million in 2025-26 after years of decline. Apiarists Advocate analysis shows retail-pack monofloral mānuka to the US up 54.1 percent to 2,862 tonnes in calendar 2025, lifting US volume share and value. Comvita’s own NA surge tracks that channel shift.
MPI’s statutory Mānuka definition (chemical and DNA markers) governs export eligibility. The private UMF trademark, administered by the UMF Honey Association, enforces multi-marker grading and packing-in-NZ rules. Comvita is longstanding licensee 1019. AFB sits under a National Pest Management Plan now managed by NZ Bee Health & Biosecurity, requiring destruction of infected hives and banning masking antibiotics. Those standards underpin NZ’s price realisation. They also raise compliance costs and slow supply response after hive attrition.
Trade policy remains a watch-item. MPI cited US tariffs and front-loading as distorting 2025 year-to-date volumes. Geopolitical freight and fuel cost spikes featured in Comvita’s March update. China consumer caution persists.
Australian peer Hive & Wellness (Capilano, Barnes Naturals, Wescobee)—private, consortium-owned—sourced more than 15,000 tonnes and booked about A$150 million gross sales in FY25 on street figures; IBISWorld puts Bravo Holdco near A$142.6 million. It hired Rothschild in mid-2025 for a strategic review after inbound interest, signalling ongoing Australasian honey M&A heat even as NZ listed pure-plays repaired.
Trade-offs the register still carries
Independence preserved upside. It also forced dilution. Rights at $0.65 sat below Grant Samuel’s range low. Holders who could not or did not follow were diluted on a base that roughly doubled. NTA of $0.74 versus a share price near $0.80 leaves limited hard-asset cushion. No dividend while repair continues.
Margin quality is the next test. Gross margin of 53.9 percent already exceeds the medium-term target near 51 percent referenced at the half. Favourable inventory cost flow-through and club overhead recovery may normalise if sell-through or pricing softens.
Channel risk shifted rather than vanished. China distributor friction eased. US club retail is now a concentrated dependency. Club pricing pressure could re-compress margins as fast as volume built them.
F&N at 19.99 percent adds Southeast Asia route-to-market and a board seat. It also creates a strategic cornerstone that can influence strategy or eventually bid. PHC at about 11.7–13 percent reshapes the register beside residual Kauri, ACC and other holders. Management frames F&N as a long-term partner already engaged on SE Asia initiatives.
Premium standards protect NZ Inc realisation. They also burden smaller operators and constrain rapid volume response if US demand keeps rising after beekeeper exits.
Second-order effects for NZ
Near term, Comvita’s net-cash balance sheet removes a visible NZX small-cap distress signal. It stabilises a major buyer of Mānuka honey and pollination services across Bay of Plenty, Waikato and East Coast catchments. The company-owned harvest lift and inventory normalisation support beekeeper cash flow after years of glut pricing.
Packaging, logistics, cold-chain and lab services tied to branded export recovery stand to benefit. Bank refinance to 2028 reduces refinancing risk for a primary processor that had sat on short-dated facilities—relevant to NZ banking exposure.
Over twelve months, sustained NA club sell-through and any China stabilisation support employment at Paengaroa manufacturing, labs and global commercial teams—Comvita employs more than 400 people. MPI’s $430 million honey forecast implies the category remains a meaningful high-value niche inside the $62 billion food-and-fibre complex. Comvita’s channel mix is a leading indicator for other branded exporters.
Two to three years out, successful embedding of F&N’s SE Asia distribution would diversify NZ Mānuka away from China cyclicality and US club concentration. That aligns with export-market diversification goals without new regulatory apparatus. A sustained recovery validates brand, science and vertical integration versus bulk export, supporting UMF and MPI authenticity regimes as economic infrastructure rather than compliance theatre.
Downside second-order paths are sharp. An authenticity scare or renewed oversupply would hit farm-gate prices and NZ’s premium reputation faster than bulk commodities. If the listed pure-play premium shrinks, further take-privates—along Australian lines—become more likely.
Historical context
Comvita listed on the NZX in November 2003 after founding in 1974–75 in the Bay of Plenty. It built vertical integration from apiaries and forests through labs and global distribution, and held B Corp status from 2023.
The 2017–19 China distributor acquisitions, partly settled in scrip to Li Wang, concentrated exposure and shareholder power in Greater China. FY23 was still profitable. FY24 and FY25 then delivered the impairment cascade as high-cost inventory, transformation spend and soft China demand reversed. Net assets collapsed from around $157 million toward $54.9 million by end-FY25.
That path is a classic premium agri-brand boom-bust: vertical integration and market concentration work until inventory and channel risk reverse. The failed Florenz scheme fits a retail-blocking pattern seen in other NZX control contests where cycle-bottom cash is rejected. The completed May 2026 recap is the alternative path—dilutive, bank-driven, and ultimately value-preserving on a cleaned balance sheet if operations hold.
Prior NZ honey transactions—Mānuka Health with Hong Leong, Egmont with Huatai, King Honey—historically cleared on mid-single-digit to low-teens EBITDA multiples depending on cycle and brand. Grant Samuel’s scheme-time EV range of $105–120 million implied roughly 7–9 times then-forecast EBITDA once turnaround delivered. Current enterprise value near $0.80 with net cash sits roughly comparable to the top of that range on repaired equity—framing the recap as preserving optionality the cash exit would have closed.
Primary-processor inventory and China cycles on the NZX more broadly (dairy, meat, horticulture analogues) show the same repair arithmetic: working-capital flush plus geographic mix shift.
The counter-argument
The strongest opposing read is straightforward. Scheme opponents argued $0.80 was a cycle-bottom lowball that undervalued long-term brand and option value. Post-failure delivery partly vindicates the “stay independent” camp—but only after heavy dilution, two lost years, and rights priced below the independent adviser’s floor.
Bears add that FY26 margins may include one-off inventory cost benefits; China is still soft and value-seeking; club retail creates new single-channel risk; NTA offers thin cushion; no dividend while repair continues; sector prices remain well below prior-cycle peaks; AFB and climate still threaten supply; and F&N at 19.99 percent could eventually bid or steer strategy in ways minorities dislike.
That read has force. The thesis against it rests on evidence already on the table: a roughly $36 million underlying operating swing, completed inventory cash release, net cash and long-dated facilities, gross margin above the prior medium-term target, and a strategic SE Asia partner with skin in the game. Sustainability—not the FY26 print itself—is the open question.
Open questions
Are 53.9 percent gross margins and NA club sell-through repeatable in FY27 once aged-stock benefits fade?
Will F&N deliver Southeast Asia volume without channel conflict or governance friction at 19.99 percent?
Does China stabilise, or remain a drag on mix and distributor economics?
What is the path and timing to a dividend given net cash but an ongoing repair narrative?
Can NZ hive and production capacity meet rising US demand without quality dilution after beekeeper exits?
Is the register end-game sustained independence, creeping F&N influence, or a renewed scheme at a higher cycle price?
FY27 interim results, club sell-through commentary, and any SE Asia order flow via F&N will answer the first cluster. MPI’s next SOPI and AFB incidence data will speak to supply. The share register and any further SPH notices will signal control dynamics.
Comvita has exited the distress chapter with net cash, repaired equity and a clearer channel map. Whether that platform compounds above the diluted post-raise base depends on margin durability, club pricing discipline, and whether Southeast Asia diversifies the book before the next China or freight shock. Investors and beekeepers alike will watch the FY27 first-half update for proof the reset sticks.
